Wohlrab J, Neubert R H H, Sommer E, Michael J
Universitätsklinik für Dermatologie und Venerologie, Martin-Luther-Universität Halle‑Wittenberg, Ernst-Grube-Str. 40, 06097, Halle (Saale), Deutschland.
An-Institut für angewandte Dermatopharmazie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Deutschland.
Hautarzt. 2017 Apr;68(4):307-315. doi: 10.1007/s00105-016-3926-8.
The combination of topical fungicide and glucocorticoids has been proven as a successful therapy of cutaneous mycoses with accompanying inflammatory reactions, particularly when used at an early stage. Various national and international therapeutic guidelines recommend this practice. In this context, two individually manufactured formulations have been developed and tested for stability: the combination of methylprednisolone aceponate-a topical glucocorticoid with the therapeutic index of 2.0-with clotrimazole and with ciclopirox olamine, respectively. This has been conducted in compliance with the requirements for quality controlled extemporaneous formulations and the legal framework of the German Pharmacy Working Regulations (Apothekenbetriebsordnung). There are now two formulations for clinical use that are microbiologically, physically, and chemically stable, which combine methylprednisolone aceponate-a glucocorticoid with a good risk-benefit ratio-with the broad-spectrum fungicides clotrimazole and, for the first time, ciclopirox olamine.
外用杀真菌剂与糖皮质激素联合使用已被证明是治疗伴有炎症反应的皮肤真菌病的一种成功疗法,尤其是在疾病早期使用时。各国和国际的各种治疗指南都推荐这种做法。在此背景下,已经研发并测试了两种单独配制的制剂的稳定性:分别是将外用糖皮质激素醋酸甲泼尼龙(治疗指数为2.0)与克霉唑以及环吡酮胺进行组合。这是按照质量控制临时制剂的要求和德国药房工作条例(《药房经营条例》)的法律框架进行的。目前有两种临床使用的制剂,它们在微生物学、物理和化学方面都很稳定,将具有良好风险效益比的糖皮质激素醋酸甲泼尼龙与广谱杀菌剂克霉唑以及首次与环吡酮胺进行了组合。